Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

Condition(s) targeted: Recurrent Childhood Acute Lymphoblastic Leukemia

Intervention: alemtuzumab (Biological); methotrexate (Drug); mercaptopurine (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: National Cancer Institute (NCI)

Official(s) and/or principal investigator(s):
Anne Angiolillo, Principal Investigator, Affiliation: COG Phase I Consortium

This phase II trial is studying how well giving alemtuzumab with or without methotrexate and mercaptopurine works in treating young patients with relapsed acute lymphoblastic leukemia. Monoclonal antibodies such as alemtuzumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as methotrexate and mercaptopurine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells.

Official title: A Phase II Study of Campath-1H in Children With Acute Lymphoblastic Leukemia in Second or Greater Relapse or Twice Induction Failure

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Response rate to Campath-1H alone

Response to combined treatment with Campath-1H and chemotherapy

Tolerability of the combination therapy evaluated by dose-limiting toxicity

Detailed description: PRIMARY OBJECTIVES: I. Determine the response rate to alemtuzumab alone and in combination with methotrexate and mercaptopurine in children with acute lymphoblastic leukemia in second or greater relapse or twice induction failure. II. Determine the toxicity of these regimens in these patients. SECONDARY OBJECTIVES: I. Determine the pharmacokinetics of alemtuzumab in these patients. II. Determine the immune response in patients treated with alemtuzumab. III. Determine changes in the number of CD52-positive cells in the blood and marrow of patients treated with alemtuzumab. IV. Determine the rate and timing of clearance of peripheral circulating lymphoblasts in patients treated with these regimens. OUTLINE: This is a multicenter study. Course 1: Patients receive alemtuzumab IV over 2 hours on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR), partial remission (PR), or cytolytic PR at day 29, or patients with CNS disease that achieve a CNS 1 or CNS 2 status, proceed to course 2. Courses 2 and 3: Patients receive alemtuzumab IV over 2 hours on days 1, 8, 15, and 22; methotrexate IV continuously over 24 hours on day 1 and then orally once daily on days 8, 15, and 22; and oral mercaptopurine once daily on days 1-28. Patients with a CR or PR at day 29 proceed to course 3. In course 3, patients receive alemtuzumab, methotrexate, and mercaptopurine as in course 2. CNS prophylaxis*: Patients receive methotrexate intrathecally on day 1 of courses 2 and 3 on day 1 of courses 2 and 3. NOTE: * CNS-negative patients receive methotrexate intrathecally on day 15 of course 1 and day 1 of courses 2 and 3.

Minimum age: N/A. Maximum age: 30 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of acute lymphoblastic leukemia (ALL)

- Meets 1 of the following criteria:

- Second or subsequent bone marrow relapse

- Failed ≥ 2 regimens for remission induction

- Patients who relapse while receiving standard ALL maintenance

chemotherapy do not require a waiting period prior to study entry

- More than 25% blasts in bone marrow aspirate (M3 marrow)

- CD52 expression on ≥ 25% of malignant cells at relapse

- Philadelphia chromosome-positive patients must have failed prior imatinib mesylate

- Performance status - Karnofsky 50-100% (for patients > 10 years of age)

- Performance status - Lansky 50-100% (for patients ≤ 10 years of age)

- At least 8 weeks

- ALT ≤ 5 times upper limit of normal (ULN)

- Bilirubin ≤ 1. 5 times ULN

- Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min

- Creatinine normal for age

- Pulse oximetry > 94%

- No evidence of dyspnea at rest

- No exercise intolerance

- No serious uncontrolled infection

- No autoimmune hemolytic anemia

- No autoimmune thrombocytopenia

- Not pregnant or nursing

- No nursing for 3 months after study participation

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 6 months after study

participation

- Seizure disorder allowed provided patients are on anticonvulsants and symptoms are

well controlled

- CNS toxicity ≤ grade 2

- No other serious uncontrolled medical condition (e. g., diabetes)

- Recovered from prior immunotherapy

- At least 8 weeks since prior biologic agents (e. g., monoclonal antibodies)

- More than 1 week since prior growth factor(s)

- At least 4 months since prior stem cell transplantation

- No evidence of active acute or chronic graft-versus-host disease post allogeneic

stem cell transplantation

- No prior alemtuzumab or its components

- No other concurrent anticancer immunomodulating agents

- Recovered from prior chemotherapy

- One dose of prior intrathecal (IT) methotrexate, cytarabine, and hydrocortisone; IT

cytarabine alone; or IT methotrexate alone allowed as part of initial diagnostic spinal tap

- Prior hydroxyurea therapy allowed

- No other concurrent anticancer chemotherapy agents

- Prior steroid therapy allowed

- More than 2 weeks since prior radiotherapy and recovered

COG Phase I Consortium, Arcadia, California 91006-3776, United States

Starting date: July 2004
Last updated: June 4, 2013